News

Study finds significant overlap in the drugs covered by Canadian public drug plans

October 11, 2017

The Patented Medicine Prices Review Board (PMPRB), through the National Prescription Drug Utilization Information System research initiative, today published Alignment Among Public Formularies in Canada - Part 1: General Overview.


PMPRB Hearing Panel issues decision in Soliris case

September 27, 2017

A Patented Medicine Prices Review Board (PMPRB) Hearing Panel issued its decision relating to the medicine Soliris, manufactured and marketed in Canada by Alexion Pharmaceuticals Inc.


After several years of low growth, public drug plan expenditures up sharply in 2015-16

May 24, 2017

$1 billion increase from 2014-15 fueled largely by new, higher-cost drugs


Statement by Patented Medicine Prices Review Board Vice-chairperson on consultation on potential changes to the Patented Medicines Regulations

May 16, 2017

Statement from Patented Medicine Prices Review Board Vice-chairperson Dr. Mitchell Levine on the launch of Health Canada’s consultation on potential changes to the Patented Medicines Regulations.


Patented Medicine Prices Review Board will hear closing arguments in the matter of the price of Soliris

April 12, 2017

Proceedings to resume April 18, 2017 in Ottawa.


PAGE 1 - 2 - 3 - 4 - 5  NEXT 25  LAST 5 
Date modified: